Williamson Andrew, Haywood Matthew, Awad Zaid
Department of Otolaryngology, Head and Neck Surgery, Charing Cross Hospital, Imperial College Healthcare, London, United Kingdom.
Ear Nose Throat J. 2021 Dec;100(10_suppl):1113S-1118S. doi: 10.1177/0145561320937627. Epub 2020 Jul 1.
Human papilloma virus (HPV)-positive oropharyngeal cancer carries a good prognosis when managed with primary chemoradiotherapy. However, the dramatically increasing rate of this disease means more patients are now developing recurrence, with surgery remaining the mainstay of treatment. Despite this, there is no agreed technique for excision of recurrent oropharyngeal cancer.
We describe the transoral robotic technique employed by our head and neck multidisciplinary team (MDT) in the management of patients with recurrent HPV positive oropharyngeal cancer and assess their symptom severity using quality of life and swallowing questionnaires.
Three (2 males:1 female, mean age 60.7 years) patients with recurrent or residual p16 positive oropharyngeal cancer following radical chemoradiotherapy were identified. All patients underwent selective neck dissection, tracheostomy, and transoral robotic surgery (TORS)-assisted partial oropharyngeal resection with the resultant defect closed with a robotic assisted radial forearm free flap (RFFF). Patient quality of life, symptom severity, and swallowing were assessed pre- and postoperatively using the University of Washington Quality of Life score and MD Anderson Dysphagia Index (MDADI).
Histopathological examination revealed complete clearance of the primary lesion in all cases. Two patients made uneventful recoveries, while one patient developed a chest infection and tracheocutaneous fistula managed conservatively. Mean inpatient stay was 15 days (range 8-27). University of Washington Quality of Life and MDADI scores showed a mild improvement in symptoms following surgery.
Surgical management of recurrent oropharyngeal cancer remains a technical challenge; however, MDT discussion and judicious use of TORS oropharyngeal resection and RFFF can result in good oncological and quality of life outcomes with acceptable postoperative complications and symptoms.
人乳头瘤病毒(HPV)阳性的口咽癌采用原发性放化疗时预后良好。然而,这种疾病发病率的急剧上升意味着现在有更多患者出现复发,手术仍是主要的治疗手段。尽管如此,对于复发性口咽癌的切除尚无公认的技术。
我们描述了头颈多学科团队(MDT)采用经口机器人技术治疗复发性HPV阳性口咽癌患者的情况,并使用生活质量和吞咽问卷评估他们的症状严重程度。
确定了3例(2例男性:1例女性,平均年龄60.7岁)在根治性放化疗后出现复发性或残留p16阳性口咽癌的患者。所有患者均接受了选择性颈部清扫、气管切开术以及经口机器人手术(TORS)辅助的部分口咽切除术,并用机器人辅助的桡侧前臂游离皮瓣(RFFF)封闭由此产生的缺损。术前和术后使用华盛顿大学生活质量评分和MD安德森吞咽指数(MDADI)评估患者的生活质量、症状严重程度和吞咽情况。
组织病理学检查显示所有病例的原发灶均完全清除。2例患者恢复顺利,1例患者发生胸部感染和气管皮肤瘘,经保守治疗。平均住院时间为15天(范围8 - 27天)。华盛顿大学生活质量和MDADI评分显示术后症状有轻微改善。
复发性口咽癌的外科治疗仍然是一项技术挑战;然而,MDT讨论以及明智地使用TORS口咽切除术和RFFF可以在术后并发症和症状可接受的情况下,带来良好的肿瘤学和生活质量结果。